SCHEMBL7671689

SCHEMBL7671689

COc1ccc(CCc2cc(C)cs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47
TUBB6 Q9BUF5 1/20 0.47
TUBB2B Q9BVA1 1/20 0.47
TUBB1 Q9H4B7 1/20 0.47
CALM1 P0DP23 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
MAPT P10636 1/20 0.44
MAOB P27338 2/20 0.42
IGF1R P08069 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28279848 0.85 SLC5A2 (0.49) MAPTALOX15ACHEIDO1KDM4E
SCHEMBL8225698 0.79 DAO (0.57) MAPTMAOBALOX15DAOKDM4E
SCHEMBL23827485 0.77 DAO (0.68) CALM1DAOF2RL1KDM4EALDH1A1
SCHEMBL16690781 0.76 DAO (0.51) MAPTDAOF2RL1ALDH1A1HPGD
SCHEMBL13038170 0.76 ACHE (0.71) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL9184500 0.75 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL834551 0.75 TAAR1 (0.73) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1244006 0.75 DAO (0.53) CALM1MAPTMAOBDAORAB9A
SCHEMBL9738011 0.73 ACHE (0.37) MAPTAOC3ACHEALDH1A1RAB9A
SCHEMBL25061966 0.73 PARP1 (0.39) CALM1MAPTCYP19A1DAOALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395730-B1 CARDIOVASCULAR DISORDERS ICAGEN, INC. 2002-05-28 US disclosed
US-6174908-B1 TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE ICAGEN, INC. 2001-01-16 US disclosed